Form 4: VolitionRx CEO's Tax Withholding Transaction Detailed in Latest SEC Filing

Salvatore Thomas Butera, CEO of Volition Veterinary, reported a transaction involving the withholding of 4,462 shares of VolitionRx common stock to cover tax obligations related to restricted stock unit settlement.

Summary

• Salvatore Thomas Butera, identified as a Director, 10% Owner, and CEO of Volition Veterinary for VolitionRx Ltd (VNRX), reported a transaction.
• The transaction date was July 1, 2025.
• The transaction involved the disposition of 4,462 shares of Common Stock at a price of $0.7679 per share.
• These shares were retained by VolitionRx for cancellation to satisfy the tax withholding obligations of Mr. Butera.
• The withholding was upon the settlement of 16,871 restricted stock units (RSUs) that were awarded in lieu of cash compensation.
• No shares were sold by Mr. Butera or VolitionRx in this transaction.
• Following the reported transaction, Mr. Butera beneficially owns 309,917 shares directly and 99,350 shares jointly with his spouse.

Sentiment

Score: 7

Explanation: The transaction is a routine tax withholding event related to executive compensation, not a sale by the insider, which is generally viewed neutrally to slightly positively as it reflects the vesting of previously awarded compensation.

Positives

• The transaction represents a routine tax withholding event upon the vesting of restricted stock units, rather than an open market sale by the insider.
• No shares were sold by the reporting person or VolitionRx in this transaction, indicating it was solely for tax compliance related to compensation.

Future Outlook

The document, a Form 4, details a past transaction related to executive compensation and does not provide any forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• "Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 16,871 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction."

Industry Context

This Form 4 filing details a common type of insider transaction where shares are withheld by the company to cover an executive's tax obligations upon the vesting of restricted stock units. This is a standard practice in executive compensation across various industries and does not indicate any unusual industry trends or competitive shifts.

Comparison to Industry Standards

• The tax withholding mechanism for restricted stock unit (RSU) vesting is a standard practice for executive compensation across publicly traded companies, aligning with common industry benchmarks for managing equity awards.
• This transaction is comparable to similar RSU vesting and tax withholding events observed at companies like Bio-Rad Laboratories or Exact Sciences, where executives receive equity as part of their compensation, and a portion is withheld to cover statutory tax liabilities.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine compensation-related transaction and not a sale of shares by the insider.
• Employees: No direct impact mentioned, but it reflects standard executive compensation practices.

Key Dates

Recommendation

Keywords

VolitionRx, VNRX, Form 4, insider transaction, stock withholding, restricted stock units, RSU, executive compensation, Salvatore Thomas Butera